Esophagus to Small Intestine
Clin Gastroenterol Hepatol. 2022;20(9):2074–82
Steroid-free deep remission at 1 year does not prevent Crohn’s disease progression: Long-term data from the TAILORIX trial
Background and aims: Crohn’s disease (CD) patients included in the Tailored Treatment With Infliximab for Active Crohn’s Disease (TAILORIX) trial started infliximab in combination with an immunosuppressant for 1 year. The aim of the present study was to determine the long-term disease course beyond the study period.
Methods: The authors compared the outcomes of patients who did or did not reach the primary end point of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileocolonoscopy at week 54. The primary outcome of this follow-up study was the progression-free survival of CD defined by anal or major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment.
Results: The 95 patients (median disease duration, 4.5 months; interquartile range [IQR], 1.0–56.6 months) analyzed, including 45 (47%) who achieved the primary end point, were followed up for a median duration of 64.2 months (IQR, 57.6–69.9 months) after the end of the study period. There was no significant difference in CD progression-free survival at 1, 3, and 5 years between patients who achieved the TAILORIX primary end point and patients who did not (p = 0.64). No difference was observed between both groups for each component of CD progression: anal surgery, major abdominal surgery, CD-related hospitalization, or the need for a new systemic CD treatment.
Conclusions: Achieving a sustained clinical remission off steroids with complete endoscopic remission in this cohort of 95 patients with early Crohn’s disease (CD) was not associated with less disease progression. Prospective trials to define the therapeutic goals that change the natural history of CD and prevent complications are needed.